Myths vs facts: AMH and longevity

The claim that AMH (Anti-Müllerian Hormone) is a direct marker for longevity is largely a myth. AMH is primarily used as a clinical indicator of ovarian reserve in women, declining with age. Some observational studies have linked higher AMH levels to later menopause and a longer reproductive window, which may indirectly correlate with increased lifespan. However, the evidence for a direct causal relationship between AMH and longevity is weak and inconsistent. Fact: AMH does not predict cardiovascular health, metabolic disease, or other age-related conditions. Most data come from cross-sectional or cohort studies with confounding factors. Additionally, AMH's role in men is poorly understood. Interpreting a single AMH value as a 'longevity score' is scientifically unsupported. Lifestyle factors—diet, exercise, stress—are far more influential on lifespan. Direct-to-consumer tests marketing AMH as a longevity biomarker overstate the evidence. Bottom line: AMH is a useful fertility marker, but not a reliable predictor of overall longevity.